[go: up one dir, main page]

MX2018002899A - Tratamiento de retinitis pigmentosa. - Google Patents

Tratamiento de retinitis pigmentosa.

Info

Publication number
MX2018002899A
MX2018002899A MX2018002899A MX2018002899A MX2018002899A MX 2018002899 A MX2018002899 A MX 2018002899A MX 2018002899 A MX2018002899 A MX 2018002899A MX 2018002899 A MX2018002899 A MX 2018002899A MX 2018002899 A MX2018002899 A MX 2018002899A
Authority
MX
Mexico
Prior art keywords
retinitis
pigmento
treatment
rpgrorf15
nucleotide sequence
Prior art date
Application number
MX2018002899A
Other languages
English (en)
Other versions
MX391209B (es
Inventor
Maclaren Robert
Fischer Dominik
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54362987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018002899(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2018002899A publication Critical patent/MX2018002899A/es
Publication of MX391209B publication Critical patent/MX391209B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11014—Rhodopsin kinase (2.7.11.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Un polinucleótido que comprende una secuencia de nucleótidos que codifica la isoforma de regulador ORF15 de GTPasa de retinitis pigmentosa (RPGRORF15), en donde la secuencia de nucleótidos que codifica RPGRORF15 ha sido optimizada en codones para aumentar la fidelidad de replicación de la secuencia.
MX2018002899A 2015-09-10 2016-09-09 Compuestos para usarse en el tratamiento o prevención de retinitis pigmentosa MX391209B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1516066.6A GB201516066D0 (en) 2015-09-10 2015-09-10 Treatment of retinitis pigmentosa
PCT/GB2016/052802 WO2017042584A1 (en) 2015-09-10 2016-09-09 Treatment of retinitis pigmentosa

Publications (2)

Publication Number Publication Date
MX2018002899A true MX2018002899A (es) 2018-09-12
MX391209B MX391209B (es) 2025-03-21

Family

ID=54362987

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002899A MX391209B (es) 2015-09-10 2016-09-09 Compuestos para usarse en el tratamiento o prevención de retinitis pigmentosa
MX2022003859A MX2022003859A (es) 2015-09-10 2018-03-07 Compuestos para usarse en el tratamiento o prevencion de retinitis pigmentosa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003859A MX2022003859A (es) 2015-09-10 2018-03-07 Compuestos para usarse en el tratamiento o prevencion de retinitis pigmentosa.

Country Status (14)

Country Link
US (3) US20180273594A1 (es)
EP (1) EP3347371B1 (es)
JP (1) JP7011580B2 (es)
KR (1) KR20180043373A (es)
CN (1) CN108699118A (es)
AU (2) AU2016320551C1 (es)
CA (1) CA2995656A1 (es)
GB (1) GB201516066D0 (es)
HK (1) HK1250727A1 (es)
IL (1) IL257881B (es)
MX (2) MX391209B (es)
RU (2) RU2020137429A (es)
SG (1) SG10202013246VA (es)
WO (1) WO2017042584A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3013632T3 (en) 2014-02-12 2025-04-14 Genentech Inc Apparatus for suprachoroidal administration of therapeutic agent
US9949874B2 (en) 2014-06-06 2018-04-24 Janssen Biotech, Inc. Therapeutic agent delivery device with convergent lumen
US9925088B2 (en) 2014-06-06 2018-03-27 Janssen Biotech, Inc. Sub-retinal tangential needle catheter guide and introducer
US10219936B2 (en) 2014-09-11 2019-03-05 Orbit Biomedical Limited Therapeutic agent delivery device with advanceable cannula and needle
US10258502B2 (en) 2014-09-18 2019-04-16 Orbit Biomedical Limited Therapeutic agent delivery device
GB201516066D0 (en) 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
US10478553B2 (en) 2016-03-09 2019-11-19 Orbit Biomedical Limited Apparatus for subretinal administration of therapeutic agent via a curved needle
US10806629B2 (en) 2016-06-17 2020-10-20 Gyroscope Therapeutics Limited Injection device for subretinal delivery of therapeutic agent
US11000410B2 (en) 2016-06-17 2021-05-11 Gyroscope Therapeutics Limited Guide apparatus for tangential entry into suprachoroidal space
US10646374B2 (en) 2016-06-17 2020-05-12 Orbit Biomedical Limited Apparatus and method to form entry bleb for subretinal delivery of therapeutic agent
US11273072B2 (en) 2017-01-13 2022-03-15 Gyroscope Therapeutics Limited Suprachoroidal injection device
US11076984B2 (en) 2017-03-13 2021-08-03 Gyroscope Therapeutics Limited Method of performing subretinal drainage and agent delivery
EP3707265A4 (en) * 2017-11-07 2021-09-01 The University of North Carolina at Chapel Hill OPTIMIZED AGA GENES AND EXPRESSION CASSETTES AND THEIR USE
JOP20210054A1 (ar) * 2018-09-21 2020-03-21 Nightstarx Ltd تركيبات وطرق لعلاج التهاب الشبكية الصباغي
JP2020174859A (ja) * 2019-04-17 2020-10-29 学校法人日本医科大学 網膜剥離が生じるリスクが低い網膜変性症（ｒｄ）モデルマウスを取得する方法
GB202005641D0 (en) * 2020-04-17 2020-06-03 Ucl Business Plc Gene therapy for bardet-biedl syndrome
CN113952472A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
WO2022021149A1 (zh) * 2020-07-29 2022-02-03 北京中因科技有限公司 Aav介导的rpgr x连锁视网膜变性的基因编辑治疗
WO2022036318A1 (en) * 2020-08-14 2022-02-17 Case Western Reserve University Plasmid vectors and nanoparticles for treating ocular disorders
US20230340042A1 (en) * 2020-09-02 2023-10-26 4D Molecular Therapeutics Inc. Codon optimized rpgrorf15 genes and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008801D0 (en) 2000-04-10 2000-05-31 Medical Res Council Sequences
US7799904B2 (en) * 2003-06-13 2010-09-21 University Of Kentucky Research Foundation Gilvocarcin gene cluster, recombinant production and use thereof
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
US20090214478A1 (en) * 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
FR2949115B1 (fr) 2009-08-14 2012-11-02 Sanofi Aventis OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
ES2362604B1 (es) 2009-12-22 2012-06-28 Bcn Peptides, S.A. Formulación tópica oftálmica de péptidos.
CN110777124A (zh) * 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
JP2015516143A (ja) * 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
CN105120901A (zh) 2012-07-11 2015-12-02 宾夕法尼亚大学托管会 Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
EP3132051B1 (en) 2014-04-15 2019-03-20 Applied Genetic Technologies Corporation Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr)
GB201412011D0 (en) 2014-07-04 2014-08-20 Ucl Business Plc Treatments
EP3191139B1 (en) 2014-07-24 2020-10-07 Massachusetts Eye & Ear Infirmary Rpgr gene therapy for retinitis pigmentosa
GB201516066D0 (en) 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa

Also Published As

Publication number Publication date
JP2018529336A (ja) 2018-10-11
KR20180043373A (ko) 2018-04-27
AU2016320551C1 (en) 2023-12-14
EP3347371A1 (en) 2018-07-18
MX2022003859A (es) 2022-06-09
GB201516066D0 (en) 2015-10-28
RU2737049C2 (ru) 2020-11-24
RU2020137429A (ru) 2022-01-17
US10836803B2 (en) 2020-11-17
AU2022200306A1 (en) 2022-02-10
AU2016320551A1 (en) 2018-03-08
JP7011580B2 (ja) 2022-01-26
IL257881A (en) 2018-05-31
IL257881B (en) 2022-12-01
RU2018112506A3 (es) 2020-01-27
SG10202013246VA (en) 2021-02-25
EP3347371B1 (en) 2023-05-10
RU2018112506A (ru) 2019-10-10
US20210130425A1 (en) 2021-05-06
WO2017042584A1 (en) 2017-03-16
CA2995656A1 (en) 2017-03-16
HK1250727A1 (zh) 2019-01-11
CN108699118A (zh) 2018-10-23
US20180273594A1 (en) 2018-09-27
MX391209B (es) 2025-03-21
AU2016320551B2 (en) 2021-11-25
US20200002392A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
MX2018002899A (es) Tratamiento de retinitis pigmentosa.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
PH12016501763B1 (en) Multispecific antibodies
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
MX389954B (es) Emulsiones de silicona.
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
PH12017502255B1 (en) Nrf2 regulators
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
PH12019502002A1 (en) Combination theraphy
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2018007352A (es) Moduladores de la actividad del complemento.
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
MX2017011223A (es) Variantes de protoxina ii y metodos de uso.
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX370412B (es) Compuesto antimicotico.
MX2017012654A (es) Variantes de protoxina-ii y metodos de uso.
MX2017007338A (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis.
MY187959A (en) Reactor
MX2017011454A (es) Procesos para preparar fluorocetólidos.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2020012065A (es) Compuestos de ciclopentano.
MX383014B (es) Formulaciones de antibióticos tópicas..
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний